Edition:
India

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

3.84USD
18 Nov 2019
Change (% chg)

-- (--)
Prev Close
$3.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
201,407
52-wk High
$16.33
52-wk Low
$2.43

Latest Key Developments (Source: Significant Developments)

Diplomat Reports Q2 Loss Per Share $2.13
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 2ND QUARTER FINANCIAL RESULTS; UPDATES 2019 GUIDANCE.Q2 REVENUE $1.288 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.23 BILLION.SEES FY LOSS PER SHARE $2.55 TO $2.69.Q2 LOSS PER SHARE $2.13.SEES FY 2019 REVENUE $4.7 BILLION TO $5.0 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.SEES 2019 REVENUE BETWEEN $4.7 AND $5.0 BILLION.RECENTLY AGREED WITH LENDERS TO AMEND CERTAIN FINANCIAL PERFORMANCE COVENANTS APPLICABLE TO CREDIT FACILITY..AMENDED CREDIT FACILITY TERMS BECAME EFFECTIVE AUGUST 6, 2019.QTRLY SPECIALTY SEGMENT REVENUE OF $1,216 MILLION, COMPARED TO $1,234 MILLION.SEES FY SPECIALTY SEGMENT REVENUE BETWEEN $4.4 AND $4.6 BILLION.FY2019 REVENUE VIEW $4.91 BILLION -- REFINITIV IBES DATA.  Full Article

Diplomat Announces Review Of Strategic Alternatives
Friday, 9 Aug 2019 

Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES.DIPLOMAT PHARMACY INC - STRATEGIC ALTERNATIVES EXPECTED TO BE CONSIDERED INCLUDE, BUT ARE NOT LIMITED TO, A SALE OR MERGER OF COMPANY.DIPLOMAT PHARMACY - RETAINED FOROS SECURITIES LLC AS FINANCIAL ADVISOR,SIDLEY AUSTIN LLP AS LEGAL ADVISOR TO ASSIST WITH STRATEGIC ALTERNATIVES REVIEW.DIPLOMAT PHARMACY - HAS RETAINED FOROS SECURITIES LLC AS FINANCIAL ADVISOR & SIDLEY AUSTIN LLP AS LEGAL ADVISOR TO ASSIST WITH ITS STRATEGIC ALTERNATIVES REVIEW.  Full Article

Diplomat Pharmacy Q1 Loss Per Share $0.19
Tuesday, 7 May 2019 

Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 1ST QUARTER FINANCIAL RESULTS.Q1 REVENUE $1.257 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.17 BILLION.SEES FY LOSS PER SHARE $0.44 TO $0.65.Q1 LOSS PER SHARE $0.19.SEES FY 2019 REVENUE $4.7 BILLION TO $5.0 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.07 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $0.34, REVENUE VIEW $4.82 BILLION -- REFINITIV IBES DATA.EXPECT TO ACHIEVE PREVIOUSLY COMMUNICATED REVENUE AND ADJUSTED EBITDA GUIDANCE FOR 2019.INCREASED 2019 GAAP NET LOSS AND EPS LOSS EXPECTATIONS DUE TO A CHANGE IN TAX FORECASTS.UPDATED OUR INCOME TAX EXPECTATION FOR YEAR TO AN EXPENSE RANGE OF $1.6 TO $2.6 MILLION.  Full Article

Diplomat Pharmacy Inc - Davison's Base Salary Will Be $450,000
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC - DAVISON'S BASE SALARY WILL BE $450,000.DIPLOMAT PHARMACY INC - COMPANY SHALL PAY KAVTHEKAR A LUMP-SUM PAYMENT OF $112,500.  Full Article

Diplomat Pharmacy Reports Q4 Loss Per Share Of $4.00
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 4TH QUARTER AND 2018 YEAR END FINANCIAL RESULTS; PROVIDES REVISED 2019 GUIDANCE.Q4 LOSS PER SHARE $4.00.Q4 REVENUE $1.361 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.41 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $4.7 BILLION TO $5.0 BILLION.SEES 2019 SPECIALTY SEGMENT REVENUE BETWEEN $4.4 AND $4.6 BILLION.SEES 2019 DILUTED LOSS PER SHARE BETWEEN $0.50 AND $0.34.SEES 2019 PBM SEGMENT REVENUE BETWEEN $0.3 AND $0.4 BILLION.MARKET CONDITIONS IN 2019 ARE SIGNIFICANTLY MORE CHALLENGING THAN EXPECTED IN SPECIALTY AND PBM BUSINESSES.DIPLOMAT PHARMACY - CO'S COST STRUCTURE NO LONGER SUPPORTED BY CURRENT BUSINESS ENVIRONMENT AND CO IS ACCELERATING OPERATIONAL EFFICIENCY INITIATIVES.DIPLOMAT - Q4 RESULTS DRIVEN BY $262 MILLION NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL, DEFINITE-LIVED INTANGIBLE ASSETS ASSOCIATED WITH PBM UNIT.FY2019 REVENUE VIEW $5.45 BILLION -- REFINITIV IBES DATA.  Full Article

Diplomat Pharmacy Says Jeff Park Resigned From Board Of Directors
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES RESIGNATION OF JEFF PARK FROM BOARD OF DIRECTORS.DIPLOMAT PHARMACY INC - ACCEPTED RESIGNATION OF DIRECTOR JEFF PARK, EFFECTIVE FEB. 22, 2019..  Full Article

Diplomat Pharmacy Sees FY 2018 Revenue $5.5 Bln To $5.6 Bln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PROVIDES UPDATED 2018 GUIDANCE AND PRELIMINARY 2019 OUTLOOK.SEES FY 2018 GAAP LOSS PER SHARE $0.00 TO $0.08.SEES FY 2018 REVENUE $5.5 BILLION TO $5.6 BILLION.CHAIRMAN & CEO GRIFFIN TO DIRECTLY LEAD CASTIARX PENDING SEARCH FOR NEW LEADERSHIP.DIPLOMAT PRESIDENT SABAN, AND CASTIARX PRESIDENT AND COO THIGPEN TO LEAVE COMPANY EFFECTIVE IMMEDIATELY.NOW EXPECTS 2018 REVENUE TO BE AT LOWER END OF $5.5 BILLION-$5.7 BILLION RANGE.SEES 2019 REVENUE IN RANGE OF $5.6 BILLION TO $5.8 BILLION.DIPLOMAT PHARMACY SEES FLAT TO LOW-SINGLE-DIGIT PERCENT YEAR-OVER-YEAR ADJUSTED EBITDA GROWTH IN 2019 COMPARED TO MID-POINT OF UPDATED 2018 GUIDANCE.SEES PRELIMINARY 2019 OUTLOOK ASSUMES A REVENUE CONTRIBUTION FROM CASTIARX OF $450 MILLION TO $500 MILLION.FY2018 REVENUE VIEW $5.56 BILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $5.86 BILLION -- REFINITIV IBES DATA.  Full Article

Diplomat Announces Q3 Earnings Per Share $0.00
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 3RD QUARTER FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.00.Q3 REVENUE $1.373 BILLION VERSUS I/B/E/S VIEW $1.42 BILLION.SEES FY 2018 LOSS PER SHARE $0.10 TO $+0.03.SEES FY 2018 REVENUE $5.5 BILLION TO $5.7 BILLION.Q3 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Diplomat Pharmacy Files For Potential Stock Shelf, Size Undisclosed
Friday, 6 Apr 2018 

April 6 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC FILES FOR POTENTIAL STOCK SHELF, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.18.Q4 EARNINGS PER SHARE $0.09.SEES FY 2018 EARNINGS PER SHARE $0.06 TO $0.17.SEES FY 2018 REVENUE $5.3 BILLION TO $5.6 BILLION.SEES 2018 ADJUSTED EPS BETWEEN $0.87 AND $0.97.‍REVENUE FOR Q4 OF 2017 WAS $1,155 MILLION, COMPARED TO $1,145 MILLION IN Q4 OF 2016​.FY2018 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $5.42 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.16, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Diplomat Pharmacy plunges after warning of 'going concern' risk

Diplomat Pharmacy Inc on Tuesday warned about its ability to continue as a going concern amid struggles with its pharmacy benefits management business, sending the company's shares falling more than 50% to a record low.